To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves second targeted AML drug Idhifa

FDA approved Idhifa enasidenib (AG-221) from Celgene Corp. (NASDAQ:CELG) and partner Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to treat adults with relapsed or refractory acute myelogenous leukemia with an isocitrate dehydrogenase

Read the full 297 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE